Virus disease EHD is advancing north with contamination in Switzerland

Published 2023년 1월 13일

Tridge summary

A recent article reports a outbreak of Epizootic Hemorrhagic Disease (EHD), spread across a region north of the Pyrenees, affecting over fifty companies and related to bluetongue. This global disease, first identified in 2012 in Turkey and 2015 in Israel, with a serotype discovered in the United States in 1995, causes symptoms in animals but cannot be transmitted from animal to animal. To contain the spread, governments in France and Spain have established a 150-kilometer buffer zone around each infected company, banning the movement of cattle, sheep, goats, and deer, with exceptions for slaughter. Currently, there is no vaccine available for the European EHD serotype, although manufacturers are considering its development. The disease is caused by an orbivirus, with different serotypes producing similar symptoms.
Disclaimer:The above summary was generated by Tridge's proprietary AI model for informational purposes.

Original content

There the disease has spread in a large area north of the Pyrenees. More than fifty companies have already been infected. The infection on a cattle farm near Bern is much further north in Europe. EHD is related to bluetongue, is also transmitted by midges and many symptoms are also similar. Animals cannot infect each other. The disease has been circulating worldwide for some time. The disease emerged in Turkey in 2012 and in Israel in 2015. Even earlier, the disease was found in Asia, Australia and Africa. The disease was first discovered in the United States in 1995. Buffer zone In France and Spain the government is not taking any lenient measures. A buffer zone of 150 kilometers is established around each infected company. There is a ban on the movement of cattle, sheep, goats and deer in these areas. There are exceptions for slaughter, among other things. Algeria has imposed an import ban on cattle from France. There is no vaccine ...
Source: Nieuwe Oogst

Would you like more in-depth insights?

Gain access to detailed market analysis tailored to your business needs.
By clicking “Accept Cookies,” I agree to provide cookies for statistical and personalized preference purposes. To learn more about our cookies, please read our Privacy Policy.